All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2004-004952-38 | Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for early breast cancer (HOT) | 2008-12-31 | due-trials |
Reported results Terminated | 2005-005721-55 | Adjuvant Cytotoxic Chemotherapy in Older Women | 2008-11-24 | due-trials |
Reported results | 2006-000687-89 | A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder | 2020-11-02 | due-trials |
Exempt Terminated | 2006-001031-22 | The Potentiation of Efficacy of Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC) by Inhibition of Akt Activation | 2011-03-29 | not-yet-due |
Other | 2006-004470-26 | Triple Negative breast cancer Trial. A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- breast cancer | not-yet-due | |
Other | 2007-003877-21 | Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC) | not-yet-due | |
Reported results | 2008-000707-28 | A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis | 2017-09-27 | due-trials |
Other | 2008-005466-30 | Effect of Perioperative AntiHER2 Therapy on Early Breast Cancer Study - Biological Phase | not-yet-due | |
Other | 2008-006295-29 | A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT) | not-yet-due | |
Reported results | 2009-012945-49 | A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) | 2016-12-12 | due-trials |
Other | 2010-021163-33 | A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS) Ensayo fase II de Cediranib en el tratamiento de pacientes con sarcoma de partes blandas alveolar ... | not-yet-due | |
Other | 2011-000601-49 | TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer. | not-yet-due | |
Other | 2011-002577-33 | A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer | not-yet-due | |
Other | 2011-004562-16 | A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | not-yet-due | |
Reported results | 2012-002592-34 | A Phase II Trial of Vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis | 2018-11-06 | due-trials |
Exempt, with results | 2012-003896-20 | TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours | 2017-11-15 | not-yet-due |
Other | 2013-000293-29 | A prospective, multi-centre, open label, non-randomised two stage phase II clinical trial evaluating the efficacy of abiraterone in patients with epithelial ovarian (including fallopian tube and prima... | not-yet-due | |
Other | 2013-004055-20 | A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223. | not-yet-due | |
Exempt, with results | 2013-004091-34 | A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer | not-yet-due | |
Other | 2013-005095-18 | A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer. | not-yet-due | |
Reported results | 2014-000887-16 | A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with ER+ primary breast canc... | 2020-03-03 | due-trials |
Reported results | 2014-003319-12 | Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) | 2019-04-23 | due-trials |
Other | 2015-001199-23 | InPACT - International Penile Advanced Cancer Trial (International Rare Cancer Initiative) | not-yet-due | |
Reported results Terminated | 2015-001361-27 | CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer. | 2020-04-09 | due-trials |
Exempt, with results | 2016-000833-40 | Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of to... | 2020-11-12 | not-yet-due |
Exempt | 2016-003141-28 | ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC) | not-yet-due | |
Other | 2017-000508-92 | c-TRAK TN: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast can... | not-yet-due | |
Other | 2017-000931-15 | PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer. | not-yet-due | |
Other | 2018-002077-21 | PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemothera... | not-yet-due | |
Other | 2018-003779-36 | ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss | not-yet-due | |
Other | 2019-001709-25 | Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer | not-yet-due | |
Exempt | 2019-003485-40 | ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) | not-yet-due | |
Other | 2019-003897-24 | PreOperative Endocrine Therapy for Individualised Care with Abemaciclib | not-yet-due |